Droniva

Composition Droniva Tablet: Each film coated tablet contains Ibandronate Monosodium Monohydrate INN equivalent to Ibandronic Acid 150 mg.

Pharmacology: The action of Ibandronic Acid on bone tissue is based on its affinity for hydroxyapatite which is part of the mineral matrix of bone. Ibandronic Acid inhibits osteoclast activity and reduces bone resorption and turnover.

Indications: Droniva is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Droniva increases bone mineral density (BMD) and reduces the incidence of vertebral fractures

 Dosage & Administration: The dose of Droniva is one 150 mg tablet once monthly on the same date of each month or as directed by the physician

Contraindication : Ibandronic Acid is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients, hypocalcemia and inability to stand or sit upright for at least 1 hour. Warnings & Precautions Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting therapy with Ibandronic Acid. Adequate intake of calcium and vitamin D is important in all patients. It is not recommended for use in patients with severe renal impairment (creatinine clearance <30 ml/min).

Side Effects :The most common side effects include back pain, allergic reaction, dyspepsia, diarrhoea, nausea, vomiting, gastritis, myalgia, headache, dizziness, vertigo etc. Use in Pregnancy & Lactation Use in pregnancy: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and foetus. Use in lactating mothers: It is not known whether it is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when it is administered to a lactating woman. Use in Children & Adolescant Safety and effectiveness in paediatric patients have not been established. Use in special groups Geriatric use: No overall differences in effectiveness or safety were observed between elderly patients and younger patients. Therefore, no dosage adjustment is necessary in the elderly. Hepatic Insufficiency: No studies have been performed to assess the pharmacokinetics of Ibandronic Acid in patients with hepatic impairment because lbandronic Acid is not metabolized in the human liver. Renal Insufficiency: It is not recommended for use in patients with severe renal impairment (creatinine clearance of < 30 ml/min).

Diplin M

Diplin

Desatrol

Dextac Capsule

Duracef

Duracef™ 200 Capsule: Each capsule contains Cefixime Trihydrate BP equivalent to Cefixime 200 mg.
Duracef™ 400 Capsule: Each capsule contains Cefixime Trihydrate BP equivalent to Cefixime 400 mg.
Duracef™ DS PFS (50 ml): Each 5 ml reconstituted suspension contains Cefixime Trihydrate BP equivalent to Cefixime 200 mg.
Duracef™ PFS (50 ml): Each 5 ml reconstituted suspension contains Cefixime Trihydrate BP equivalent to Cefixime 100 mg.
Duracef™ PFS (30 ml): Each 5 ml reconstituted suspension contains Cefixime Trihydrate BP equivalent to Cefixime 100 mg.
Duracef™ Paediatric Drops (21 ml): Each ml reconstituted suspension contains Cefixime Trihydrate BP equivalent to Cefixime 25 mg.
Duracef™ Max PFS (10 ml): Each 5 ml reconstituted suspension contains Cefixime Trihydrate BP equivalent to Cefixime 500 mg.
Duracef™ Max PFS (20 ml): Each 5 ml reconstituted suspension contains Cefixime Trihydrate BP equivalent to Cefixime 500 mg.